4-Azaspiro[2.4]heptane-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-Azaspiro[2.4]heptane-4-carboxylic acid
• 英文别名: 4-azaspiro[2.4]heptane-4-carboxylic acid
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: KGGAXKVVJPPMCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
  申请人：Zhang Hui

  公开号：US20140179638A1

  公开（公告）日：2014-06-26

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , R 12 , R 13a and R 13b are each independently as defined in the description.

  本发明涉及由式(I)表示的9-氨甲基取代四环素化合物，或其药学上可接受的盐、前药、溶剂化合物或异构体，以及制备这些化合物的方法和包含其的药物组合物。本发明还涉及这些化合物在制备用于治疗和/或预防四环素药物敏感疾病的药物中的用途。其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a和R13b各自独立地如描述中所定义。
• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND
  申请人：KBP Biosciences Co., Ltd.

  公开号：EP2738156A1

  公开（公告）日：2014-06-04

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

  本发明涉及由式(I)代表的9-氨甲基取代的四环素化合物，或其药学上可接受的盐、原药、溶媒或异构体，以及制备这些化合物和包含这些化合物的药物组合物的方法。本发明还涉及这些化合物在制备治疗和/或预防四环素药物敏感性疾病的药物中的用途。 其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a 和 R13b 各自独立地如描述中所定义。
• 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3924058A1

  公开（公告）日：2021-12-22
• US9365499B2
  申请人：——

  公开号：US9365499B2

  公开（公告）日：2016-06-14
• [EN] 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE 5-ALKYL-PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2020167706A1

  公开（公告）日：2020-08-20

  The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.